Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL6390884 | 0.98 | GAA (0.34) | HPGDGAACYP1A2CXCR4 | |
| Formamide SCHEMBL1934585 | 0.96 | CHRM2 (0.34) | CHRM2 | |
| Formamide SCHEMBL6387852 | 0.93 | CHRM2 (0.33) | CHRM2 | |
| SCHEMBL27625029 | 0.87 | HPGD (0.35) | HPGDGAACYP1A2MEN1ALDH1A1 | |
| SCHEMBL2442076 | 0.86 | — | — | |
| SCHEMBL223265 | 0.86 | — | — | |
| SCHEMBL5242776 | 0.86 | — | — | |
| Formic Acid SCHEMBL23929287 | 0.85 | HPGD (0.38) | HPGDGAACYP1A2CXCR4ALDH1A1 | |
| SCHEMBL13078692 | 0.84 | CYP1A2 (0.45) | HPGDGAACYP1A2MEN1ALDH1A1 | |
| Water SCHEMBL5183137 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024114814-A1 | JAK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | ONQUALITY PHARMACEUTICALS CHINA LTD (CN) | 2024-06-06 | — | — | WO | claimed |
| EP-3630749-B9 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | claimed |
| CN-111163839-B | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-111386261-B | Coumarin derivatives, process for their preparation and their use in the treatment of cancer | 利德发现中心有限责任公司 | 2024-03-22 | — | — | CN | claimed |
| CN-117729916-A | Benzodioxane modulators of leukotriene A4 hydrolase (LTA 4H) for the prevention and treatment of aging-related diseases | 万能溶剂有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117412959-A | Substituted 1-aryl-1 '-heteroaryl compounds, substituted 1,1' -biaryl compounds, and methods of use thereof | 爱彼特生物制药公司 | 2024-01-16 | — | — | CN | claimed |
| EP-3630749-B1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | claimed |
| CN-117136060-A | Methods of treating inflammatory diseases | 里邦医疗公司 | 2023-11-28 | — | — | CN | claimed |
| EP-3684762-B1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2023-05-03 | — | — | EP | claimed |
| CN-115819328-A | Memantine urea derivative, preparation method thereof and application thereof in preparing medicine for treating soluble epoxide hydrolase mediated diseases | 沈阳药科大学 | 2023-03-21 | — | — | CN | claimed |
| CN-112135824-A | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2020-12-25 | — | — | CN | claimed |
| CN-111699176-A | Quinazolinones as PARP14 inhibitors | 里邦医疗公司 | 2020-09-22 | — | — | CN | claimed |
| CN-111465600-A | Pharmaceutical compounds | 瑞威有限公司 | 2020-07-28 | — | — | CN | claimed |
| CN-111386261-A | Coumarin derivatives, preparation method thereof and application thereof in cancer treatment | 利德发现中心有限责任公司 | 2020-07-07 | — | — | CN | claimed |
| CN-111163839-A | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2020-05-15 | — | — | CN | claimed |
| CN-110869359-A | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | 加拉帕戈斯股份有限公司 | 2020-03-06 | — | — | CN | claimed |
| CN-107406451-B | Pyrrolopyrimidines and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | 福马治疗股份有限公司 | 2019-12-17 | — | — | CN | claimed |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | claimed |
| EP-2024354-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | Albireo AB (SE) | 2009-02-18 | — | — | EP | claimed |
| WO-2007136324-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2007-11-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | HPGD 752/4885GAA 4358/4885CYP1A2 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.